China Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the biotech’s six biosimilar products, as well as its main technology platforms – including the foundational Human Antibody Transgenic Mouse platform…
Luye Pharma What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the late 1980s that there were no local Chinese companies doing what I wanted to do at the time so I saw there was an…
See our Cookie Privacy Policy Here
